7月31日，迈威（上海）生物科技股份有限公司（股票代码：02493，以下简称“迈威生物-B”）公布，其自主研发的9MW5211注射液用于原发性胆汁性胆管炎（PBC）适应症的临床试验申请已获国家药品监督管理局（NMPA）批准。该试验的《药物临床试验批准通知书》编号为2026LP023302，NMPA于2026年5月26日受理该申请并作出同意开展临床试验的审评结论。
7月31日，迈威（上海）生物科技股份有限公司（股票代码：02493，以下简称“迈威生物-B”）公布，其自主研发的9MW5211注射液用于原发性胆汁性胆管炎（PBC）适应症的临床试验申请已获国家药品监督管理局（NMPA）批准。该试验的《药物临床试验批准通知书》编号为2026LP023302，NMPA于2026年5月26日受理该申请并作出同意开展临床试验的审评结论。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.